Journal article
Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2017
DOI: 10.1111/ajco.12699
Abstract
First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring a sensitizing mutation in the EGFR gene. Unfortunately, resistance to these therapies often occurs within 10 months of commencing treatment and is mostly commonly due to the development of the EGFR T790M mutation. Treatment with the third-generation EGFR TKI, osimertinib can prolong progression free survival in patients with the T790M mutation, so it is important to determine the resistance mechanism in order to plan ongoing therapeutic strategies. Here we review the evidence and make recommendations for the ti..
View full abstractGrants
Funding Acknowledgements
AstraZeneca Australia provided funding for development of the publication. Medical writing services, funded by AstraZeneca, were provided by Katie Burslem, CMPP from WriteSource Medical Pty Ltd.